Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- IGF1R IBP5 IGF-BP5 IGFBP-5 WB P-24593 IGF1 IGF 1 1R glycosylation phosphorylation nuclear localization signal antibodies
- Product Overview:
Insulin-like growth factor binding protein 5 (IGFBP5) is a secreted protein that binds IGF-1 and restricts it from accessing its cell-surface receptor (IGF-1R). This aids in regulation of cell growth, differentiation, and apoptosis.{14904} IGFBP5 also displays IGF-1 independent transactivational activity in the nucleus.{14903} Some tissues and cell types with higher levels of this protein include kidney, heart, placenta, and skeletal cells.{14902} Expression has also been reported in a variety of cancers, including mammary gland and neuroblastoma.{14904,14899} Cayman’s IGFBP5 Polyclonal Antibody is directed against a synthetic peptide sequence that partially overlaps the IGFBP5 region identified as a nuclear localization signal.{14903} IGFBP5 (272 amino acids) has a calculated molecular weight of 30.6 kDa. Cayman’s IGFBP5 Polyclonal Antibody can be used for Western blot applications and recognizes IGFBP5 at 33 kDa from mouse and rat samples. Reported glycosylation and phosphorylation sites may explain the band migration to 33 kDa.{14904,14901}
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.